Kymera Therapeutics (KYMR) Stock Forecast & Price Target

$44.11 +0.06 (+0.14%)

(As of 11/21/2024 ET)

Kymera Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
4

Buy
12

Based on 16 Wall Street analysts who have issued ratings for Kymera Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 4 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for KYMR.

Consensus Price Target

$52.13
18.19% Upside

According to the 16 analysts' twelve-month price targets for Kymera Therapeutics, the average price target is $52.13. The highest price target for KYMR is $74.00, while the lowest price target for KYMR is $30.00. The average price target represents a forecasted upside of 18.19% from the current price of $44.11.

Get the Latest News and Ratings for KYMR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors.

KYMR Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	7 Buy rating(s)
Hold	4 Hold rating(s)	4 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$52.13	$49.00	$45.90	$39.30
Forecasted Upside	18.19% Upside	1.30% Upside	-3.93% Downside	99.09% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

KYMR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

KYMR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Kymera Therapeutics Stock vs. The Competition

Type	Kymera Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.81	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	18.19% Upside	26,390.75% Upside	8.55% Upside
News Sentiment Rating	Neutral News See Recent KYMR News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/18/2024	Stephens 4 of 5 stars	S. Loganathan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00	+54.91%
11/6/2024	Morgan Stanley 3 of 5 stars		Boost Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $49.00	+2.75%
11/4/2024	UBS Group 4 of 5 stars		Lower Target	Buy ➝ Buy	$80.00 ➝ $74.00	+57.78%
11/1/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $52.00	+12.99%
11/1/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $53.00	+14.15%
9/27/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$52.00 ➝ $56.00	+13.20%
Get the Latest News and Ratings for KYMR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/9/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	F. Khurshid Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/9/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$60.00	+32.16%
8/26/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$65.00	+36.04%
8/12/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$30.00 ➝ $38.00	-10.69%
7/9/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$31.00 ➝ $36.00	-8.70%
6/17/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00	+38.18%
2/27/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$39.00 ➝ $56.00	+27.88%
2/23/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$34.00 ➝ $47.00	+11.96%
2/23/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$35.00 ➝ $55.00	+35.84%
1/3/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$45.00 ➝ $30.00	+18.34%
8/4/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$36.00 ➝ $37.00	+55.92%
5/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform
12/16/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$40.00 ➝ $52.00	+95.86%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:05 PM ET.

KYMR Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Kymera Therapeutics is $52.13, with a high forecast of $74.00 and a low forecast of $30.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last year. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" KYMR shares.
: According to analysts, Kymera Therapeutics's stock has a predicted upside of 18.19% based on their 12-month stock forecasts.
: Over the previous 90 days, Kymera Therapeutics's stock had 2 upgrades by analysts.
: Kymera Therapeutics has been rated by research analysts at Guggenheim, Leerink Partners, Leerink Partnrs, Morgan Stanley, Oppenheimer, Stephens, Truist Financial, UBS Group, and Wolfe Research in the past 90 days.
: Analysts like Kymera Therapeutics more than other "medical" companies. The consensus rating score for Kymera Therapeutics is 2.81 while the average consensus rating score for "medical" companies is 2.80. Learn more on how KYMR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Buffett Dumps $982 Million in BofA Stock—What Does He Know? (Ad)

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

This page (NASDAQ:KYMR) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Stock Forecast & Price Target